4. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z,
et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 2020;181:894–904.
7. Lin SM, Lin SC, Hsu JN, Chang CK, Chien CM, Wang YS,
et al. Structure-based stabilization of non-native protein-protein interactions of coronavirus nucleocapsid proteins in antiviral drug design. J Med Chem 2020;63:3131–3141.
9. Marchler-Bauer A, Anderson JB, Derbyshire MK, DeWeese-Scott C, Gonzales NR, Gwadz M,
et al. CDD: a conserved domain database for interactive domain family analysis. Nucleic Acids Res 2007;35:D237–D240.
11. Huang B. MetaPocket: a meta approach to improve protein ligand binding site prediction. OMICS 2009;13:325–330.
12. Rizvi SM, Shakil S, Haneef M. A simple click by click protocol to perform docking: AutoDock 4.2 made easy for non-bioinformaticians. EXCLI J 2013;12:831–857.
13. Fuhrmann J, Rurainski A, Lenhof HP, Neumann D. A new Lamarckian genetic algorithm for flexible ligand-receptor docking. J Comput Chem 2010;31:1911–1918.
16. Moghadamtousi SZ, Kadir HA, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Res Int 2014;2014:186864.
17. Ashfaq UA, Idrees S. Medicinal plants against hepatitis C virus. World J Gastroenterol 2014;20:2941–2947.
18. Mohan M, James P, Valsalan R, Nazeem PA. Molecular docking studies of phytochemicals from
Phyllanthus niruri against hepatitis B DNA polymerase. Bioinformation 2015;11:426–431.
19. Doki T, Tarusawa T, Hohdatsu T, Takano T.
In vivo antiviral effects of U18666A against type I feline infectious peritonitis virus. Pathogens 2020;9:67.
21. Rafe T, Shawon PA, Salem L, Chowdhury NI, Kabir F, Bin Zahur SM,
et al. Preventive role of resveratrol against inflammatory cytokines and related diseases. Curr Pharm Des 2019;25:1345–1371.
22. Kaliyaperumal S, Periyasamy K, Balakrishnan U, Palanivel P, Egbuna C. Antiviral phytocompounds for drug development: a data mining studies. In: Phytochemicals as Lead Compounds for New Drug Discovery (Egbuna C, Kumar S, Ifemeje J, Ezzat S, Kaliyaperumal S, eds.). Amsterdam: Elsevier, 2020. pp. 239-244.
23. Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, Fan KW,
et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2004;31:69–75.
25. Jagadeb M, Rath SN, Sonawane A. In silico discovery of potential drug molecules to improve the treatment of isoniazid-resistant
Mycobacterium tuberculosis. J Biomol Struct Dyn 2019;37:3388–3398.
26. Kadioglu O, Saeed M, Johannes Greten H, Efferth T. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning. Preprint at
http://dx.doi.org/10.2471/BLT.20.255943 (2020).
28. Sarma P, Shekhar N, Prajapat M, Avti P, Kaur H, Kumar S,
et al. In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain). J Biomol Struct Dyn 2020 May 18 [Epub].
https://doi.org/10.1080/07391102.2020.1753580.
30. Kang S, Yang M, Hong Z, Zhang L, Huang Z, Chen X,
et al. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B 2020;10:1228–1238.
31. Johns C. Glycyrrhizic acid toxicity caused by consumption of licorice candy cigars. CJEM 2009;11:94–96.
32. Chen R, Lin J, Hong J, Han D, Zhang AD, Lan R,
et al. Potential toxicity of quercetin: the repression of mitochondrial copy number via decreased POLG expression and excessive TFAM expression in irradiated murine bone marrow. Toxicol Rep 2014;1:450–458.